Companies: | 51,220 |
Products and Services: | 2,875 |
Articles and publications: | 31,357 (+4) |
Tenders & Vacancies: | 17 |
Apigenin is a yellow crystalline powder that belongs to the flavone class, the aglycone of many glycosides that naturally occurs. It is water-insoluble but soluble in organic solvents. Wide range of pharmacological activities are ascribed to apigenin such as anti-toxicant, anti-inflammatory anti-cancer, etc. Apigenin is a plant extract to diagnose a variety of diseases and inflammatory conditions.
Apigenin is a natural phytochemical present in many vegetables and fruits, but the most common sources are celeriac, chamomile tea, parsley and celery. Apigenin is especially abundant in chamomile plant flowers, accounting for 68% of total flavonoids. Apigenin which are present in the plants are used to treat various diseases including hepatitis, diabetes, cancer arthritis, leishmanial ulcers, dysentery, blennorrhagia, inflammation and haemorrhoids.
Apigenin is a single form of metabolic enzyme inhibiter that inhibits CYP2C9, which is responsible for drug metabolism. Apigenin (5, 7, 4-trihydroxy flavones) is present in very small quantities in the human diet. This composite aspect, such as distribution of bioavailability or excretion in humans. Apigenin is defined as a bioflavonoid of a non-mutagenic nature. Owing to these properties, it is anticipated to boost the growth of Apigenin market is over the forecast period.
Request A Sample-https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=78114
Apigenin is one of the most renowned extract among the large range of phenolic compounds, possessing countless nutritional and organoleptic attributes. However, it may also contribute to its beneficial health effects, which may lead to the potential inclusion of nutraceutical formulations. A deeper understanding of apigenin mode of action will be of utmost importance for future nutraceutical applications due to the variety of pharmacological activities and significance to human health.
The different interventions surrounding the potential therapeutic activity of apigenin were researched, such as apoptosis, cell cycle arrest, antioxidant function and anti-inflammatory. It is often believed that apigenin tends to decrease the vascular permeability, which seems to be a defensive strategy against oxidative stress, such as free-radical scavenging.
Apigenin’s anti-diabetic properties can be attributed to its ability to increase insulin secretion, inhibit α-glucosidase activity, to interact with and neutralize reactive oxygen species (ROS) in the cell, that together help to prevent diabetic complications. Apigenin has also demonstrated the ability to deliver moderate nitric oxide (NO) to endothelial cells, thereby reducing the risk of endothelial cell damage and hyperglycemic dysfunction.
Enquiry Before Buying:https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=78114
In general bioactive compounds of plant origin like apigenin, which decreases cancer incidence. High intakes of flavonoids from fruits and vegetables are considered to be inversely associated with the risk of cancer. It was found in the study that there is an inverse correlation between flavonoid intake and incidence of all cancer types, which also provides substantial evidence of a protective effect of flavonoids against lung cancer.
The link between dietary flavonoids and their protective function as well as the reduction of cancer risk was examined, amongst others, in studies on ovarian cancer, breast cancer and the recurring risk of neoplasia with resected patients with colorectal cancer.
Potential chemotherapeutic modality of apigenin in comparison with certain other covalently linked flavonoids despite its low intrinsic toxicity and remarkable effect on normal against cancer cells. Growing demand for apigenin for its anticancer effect is expected to drive the market in the near future.